Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 L755S||colorectal cancer||conflicting||Neratinib||Preclinical||Actionable||In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).||26243863|
|ERBB2 L755S||colorectal cancer||conflicting||Neratinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Nerlynx (neratinib) treatment resulted in increased tumor growth compared to vehicle control in cell line xenograft models of colorectal cancer harboring ERBB2 (HER2) L755S (PMID: 31588020).||31588020|
|PubMed Id||Reference Title||Details|
|(26243863)||HER2 activating mutations are targets for colorectal cancer treatment.||Full reference...|
|(31588020)||Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.||Full reference...|